IP Library Granted Patent US 11,395,825
Granted Patent B2
US 11,395,825 · App. 16/751,177 · Granted Jul 26, 2022

Compositions and methods for treating eyes and methods of preparation

Inventors: Anthony Sampietro (Los Angeles, CA); Damien Goldberg (Manhattan Beach, CA); Amy Frost (Stevensville, MT); Brian Holdorf (Missoula, MT)
Assignee: OCULAR SCIENCE, INC.
A61K31/573A61K9/0048A61K31/137A61K31/167A61K31/216A61K31/382A61K31/407A61K31/4709A61K31/496A61K31/498A61K31/5377A61K31/5575A61P27/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,395,825
App. No.
16/751,177
Granted
Jul 26, 2022
Kind
B2
Abstract

Pharmaceutical compositions, methods for treating various issues of the eyes, and methods of preparing such compositions are described. These pharmaceutical compositions may be for treating glaucoma, in preparation of eye surgery, during eye surgery, various post-op care (e.g., after cataract surgery, laser eye surgery, and the like), for treating dry eyes, and/or for promoting eyelash growth. These pharmaceutical compositions may comprise such active ingredients (APIs) as: timolol, latanoprost, brimonidine tartrate, dorzolamide, moxifloxacin HCl, dexamethasone PO4, phenylephrine HCl, lidocaine HCl, ketorolac tromethamine, bromfenac, prednisolone PO4, gatifloxacin, amniotic cytokine extract (ACE), prostaglandin E2 (PGE2), and combinations thereof.

Claims (23)

1. A method for treating an ocular condition of an eye; comprising administering a pharmaceutical composition at, in, or around the eye via a delivery device and per a predetermined dosing regimen, wherein:

the pharmaceutical composition is free of preservatives;

the pharmaceutical composition comprises one of:

(1) phenylephrine HCl 1.5%, lidocaine HCl 1%, and ketorolac tromethamine 0.3%; or

(2) phenylephrine HCl 1.5%, lidocaine HCl 1%, and bromfenac 0.01%;

wherein these percentages are with respect to weight per volume; and

wherein the ocular condition is glaucoma, care after cataract surgery, care after LASIK surgery, care for a retina of the eye after cataract surgery, care for a retina of the eye after retina surgery, in preparation for an intraocular procedure, or during the intraocular procedure.

2. The method according to claim 1 , wherein the delivery device is an eye dropper or a syringe for intra-cameral injection.

3. The method of claim 2 , wherein the delivery device is the eye dropper, wherein the eye dropper is a light resistant bottle.

4. The method according to claim 1 , wherein the predetermined dosing regimen is once per day, twice per day, three times per day, once every other day, once per week, once every other week, or once monthly.

5. The method according to claim 1 , wherein the pharmaceutical composition comprises phenylephrine HCl 1.5%, lidocaine HCl 1%, and ketorolac tromethamine 0.3%.

6. The method of claim 5 , wherein the pharmaceutical composition has a pH of 6.5.

7. The method according to claim 1 , wherein the pharmaceutical composition comprises phenylephrine HCl 1.5%, lidocaine HCl 1%, and bromfenac 0.01%.

8. The method of claim 7 , wherein the pharmaceutical composition has a pH of 7.0 to 7.2.

9. The method of claim 1 , wherein the ocular condition is in preparation for the intraocular procedure or during the intraocular procedure.

10. The method of claim 9 , wherein the intraocular procedure is cataract surgery.

11. The method of claim 10 , wherein the method further reduces post-operation infections after the cataract surgery.

12. The method of claim 10 , wherein the method further improves the speed of recovery and quality of vision improvement of the cataract surgery.

13. The method of claim 1 , wherein the ocular condition is the care after cataract surgery, the care after LASIK surgery, the care for a retina of the eye after cataract surgery, or the care for a retina of the eye after retina surgery.

14. The method of claim 1 , wherein the method reduces post-operation infections after the cataract surgery, the LASIK surgery, or the retina surgery.

15. The method of claim 1 , wherein the method improves the speed of recovery and quality of vision improvement of the cataract surgery, the LASIK surgery, or the retina surgery.

16. The method of claim 1 , wherein the pharmaceutical composition is stored at room temperature.

17. The method according to claim 1 , wherein the pharmaceutical composition has a beyond-use date of at least 180 days.

Assignments (4)
SECURITY INTEREST Recorded Dec 17, 2025
From: OCULAR SCIENCE, INC.
To: CHICAGO ATLANTIC ADMIN, LLC
Reel/Frame 073251/0162 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2020
From: OSRX, INC.
To: OCULAR SCIENCE, INC.
Reel/Frame 052652/0942 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2020
From: HOLDORF, BRIAN
To: OSRX, INC.
Reel/Frame 051620/0787 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2020
From: FROST, AMY; SAMPIETRO, ANTHONY; GOLDBERG, DAMIEN
To: OSRX, INC.
Reel/Frame 051604/0557 →
Continuity (5)
Continuation 15971936 · May 4, 2018
Provisional Application 62646287 · Mar 21, 2018
Provisional Application 62621299 · Jan 24, 2018
Provisional Application 62501390 · May 4, 2017
Related Publication 20200222428A1 · Jul 16, 2020